img

Global Bispecific Antibody Molecular Drug Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Bispecific Antibody Molecular Drug Market Insights, Forecast to 2034

Bispecific antibody molecular drugs are developed on the basis of monoclonal antibodies and are regarded as the second-generation antibody therapy for tumor treatment. Bispecific antibody molecules do not exist in the natural state and can only be prepared artificially. Its development is through the co-expression of two different H chains and two different L chains. Therefore, bispecific antibodies can specifically bind 2 different antigens.
Global Bispecific Antibody Molecular Drug market is expected to reach to US$ 535 million in 2024, with a positive growth of %, compared with US$ 500 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Bispecific Antibody Molecular Drug industry is evaluated to reach US$ 802.9 million in 2029. The CAGR will be 7.0% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Bispecific Antibody Molecular Drug market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Bispecific Antibody Molecular Drug market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


MacroGenics
Xencor
Medimmune
Merrimsck
Merus NV
Genentech
Zhongshan Kangfang Biology Medicine
Sichuan Baili Pharmaceutical
Alphamab Oncology
Amgen
Segment by Type
EGFR×HER3 Target
PD-1×CTLA-4 Target
HER2×HER3 Target

Segment by Application


Pancreatic Cancer
Breast Cancer
Colorectal Cancer
Non-Small Cell Lung Cancer
Solid Tumor
Others

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Bispecific Antibody Molecular Drug plant distribution, commercial date of Bispecific Antibody Molecular Drug, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Bispecific Antibody Molecular Drug introduction, etc. Bispecific Antibody Molecular Drug Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Bispecific Antibody Molecular Drug
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Bispecific Antibody Molecular Drug Product Introduction
1.2 Market by Type
1.2.1 Global Bispecific Antibody Molecular Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 EGFR×HER3 Target
1.2.3 PD-1×CTLA-4 Target
1.2.4 HER2×HER3 Target
1.3 Market by Application
1.3.1 Global Bispecific Antibody Molecular Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Pancreatic Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Non-Small Cell Lung Cancer
1.3.6 Solid Tumor
1.3.7 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Bispecific Antibody Molecular Drug Sales Estimates and Forecasts 2018-2029
2.2 Global Bispecific Antibody Molecular Drug Revenue by Region
2.2.1 Global Bispecific Antibody Molecular Drug Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Bispecific Antibody Molecular Drug Revenue by Region (2018-2024)
2.2.3 Global Bispecific Antibody Molecular Drug Revenue by Region (2024-2029)
2.2.4 Global Bispecific Antibody Molecular Drug Revenue Market Share by Region (2018-2029)
2.3 Global Bispecific Antibody Molecular Drug Sales Estimates and Forecasts 2018-2029
2.4 Global Bispecific Antibody Molecular Drug Sales by Region
2.4.1 Global Bispecific Antibody Molecular Drug Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Bispecific Antibody Molecular Drug Sales by Region (2018-2024)
2.4.3 Global Bispecific Antibody Molecular Drug Sales by Region (2024-2029)
2.4.4 Global Bispecific Antibody Molecular Drug Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Bispecific Antibody Molecular Drug Sales by Manufacturers
3.1.1 Global Bispecific Antibody Molecular Drug Sales by Manufacturers (2018-2024)
3.1.2 Global Bispecific Antibody Molecular Drug Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Bispecific Antibody Molecular Drug in 2022
3.2 Global Bispecific Antibody Molecular Drug Revenue by Manufacturers
3.2.1 Global Bispecific Antibody Molecular Drug Revenue by Manufacturers (2018-2024)
3.2.2 Global Bispecific Antibody Molecular Drug Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Bispecific Antibody Molecular Drug Revenue in 2022
3.3 Global Key Players of Bispecific Antibody Molecular Drug, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Bispecific Antibody Molecular Drug Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Bispecific Antibody Molecular Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Bispecific Antibody Molecular Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Bispecific Antibody Molecular Drug, Product Offered and Application
3.8 Global Key Manufacturers of Bispecific Antibody Molecular Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Bispecific Antibody Molecular Drug Sales by Type
4.1.1 Global Bispecific Antibody Molecular Drug Historical Sales by Type (2018-2024)
4.1.2 Global Bispecific Antibody Molecular Drug Forecasted Sales by Type (2024-2029)
4.1.3 Global Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2029)
4.2 Global Bispecific Antibody Molecular Drug Revenue by Type
4.2.1 Global Bispecific Antibody Molecular Drug Historical Revenue by Type (2018-2024)
4.2.2 Global Bispecific Antibody Molecular Drug Forecasted Revenue by Type (2024-2029)
4.2.3 Global Bispecific Antibody Molecular Drug Revenue Market Share by Type (2018-2029)
4.3 Global Bispecific Antibody Molecular Drug Price by Type
4.3.1 Global Bispecific Antibody Molecular Drug Price by Type (2018-2024)
4.3.2 Global Bispecific Antibody Molecular Drug Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Bispecific Antibody Molecular Drug Sales by Application
5.1.1 Global Bispecific Antibody Molecular Drug Historical Sales by Application (2018-2024)
5.1.2 Global Bispecific Antibody Molecular Drug Forecasted Sales by Application (2024-2029)
5.1.3 Global Bispecific Antibody Molecular Drug Sales Market Share by Application (2018-2029)
5.2 Global Bispecific Antibody Molecular Drug Revenue by Application
5.2.1 Global Bispecific Antibody Molecular Drug Historical Revenue by Application (2018-2024)
5.2.2 Global Bispecific Antibody Molecular Drug Forecasted Revenue by Application (2024-2029)
5.2.3 Global Bispecific Antibody Molecular Drug Revenue Market Share by Application (2018-2029)
5.3 Global Bispecific Antibody Molecular Drug Price by Application
5.3.1 Global Bispecific Antibody Molecular Drug Price by Application (2018-2024)
5.3.2 Global Bispecific Antibody Molecular Drug Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Bispecific Antibody Molecular Drug Market Size by Type
6.1.1 US & Canada Bispecific Antibody Molecular Drug Sales by Type (2018-2029)
6.1.2 US & Canada Bispecific Antibody Molecular Drug Revenue by Type (2018-2029)
6.2 US & Canada Bispecific Antibody Molecular Drug Market Size by Application
6.2.1 US & Canada Bispecific Antibody Molecular Drug Sales by Application (2018-2029)
6.2.2 US & Canada Bispecific Antibody Molecular Drug Revenue by Application (2018-2029)
6.3 US & Canada Bispecific Antibody Molecular Drug Market Size by Country
6.3.1 US & Canada Bispecific Antibody Molecular Drug Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Bispecific Antibody Molecular Drug Sales by Country (2018-2029)
6.3.3 US & Canada Bispecific Antibody Molecular Drug Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Bispecific Antibody Molecular Drug Market Size by Type
7.1.1 Europe Bispecific Antibody Molecular Drug Sales by Type (2018-2029)
7.1.2 Europe Bispecific Antibody Molecular Drug Revenue by Type (2018-2029)
7.2 Europe Bispecific Antibody Molecular Drug Market Size by Application
7.2.1 Europe Bispecific Antibody Molecular Drug Sales by Application (2018-2029)
7.2.2 Europe Bispecific Antibody Molecular Drug Revenue by Application (2018-2029)
7.3 Europe Bispecific Antibody Molecular Drug Market Size by Country
7.3.1 Europe Bispecific Antibody Molecular Drug Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Bispecific Antibody Molecular Drug Sales by Country (2018-2029)
7.3.3 Europe Bispecific Antibody Molecular Drug Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Bispecific Antibody Molecular Drug Market Size
8.1.1 China Bispecific Antibody Molecular Drug Sales (2018-2029)
8.1.2 China Bispecific Antibody Molecular Drug Revenue (2018-2029)
8.2 China Bispecific Antibody Molecular Drug Market Size by Application
8.2.1 China Bispecific Antibody Molecular Drug Sales by Application (2018-2029)
8.2.2 China Bispecific Antibody Molecular Drug Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Bispecific Antibody Molecular Drug Market Size by Type
9.1.1 Asia Bispecific Antibody Molecular Drug Sales by Type (2018-2029)
9.1.2 Asia Bispecific Antibody Molecular Drug Revenue by Type (2018-2029)
9.2 Asia Bispecific Antibody Molecular Drug Market Size by Application
9.2.1 Asia Bispecific Antibody Molecular Drug Sales by Application (2018-2029)
9.2.2 Asia Bispecific Antibody Molecular Drug Revenue by Application (2018-2029)
9.3 Asia Bispecific Antibody Molecular Drug Sales by Region
9.3.1 Asia Bispecific Antibody Molecular Drug Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Bispecific Antibody Molecular Drug Revenue by Region (2018-2029)
9.3.3 Asia Bispecific Antibody Molecular Drug Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Market Size by Type
10.1.1 Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Market Size by Application
10.2.1 Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Sales by Country
10.3.1 Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 MacroGenics
11.1.1 MacroGenics Company Information
11.1.2 MacroGenics Overview
11.1.3 MacroGenics Bispecific Antibody Molecular Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 MacroGenics Bispecific Antibody Molecular Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 MacroGenics Recent Developments
11.2 Xencor
11.2.1 Xencor Company Information
11.2.2 Xencor Overview
11.2.3 Xencor Bispecific Antibody Molecular Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Xencor Bispecific Antibody Molecular Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Xencor Recent Developments
11.3 Medimmune
11.3.1 Medimmune Company Information
11.3.2 Medimmune Overview
11.3.3 Medimmune Bispecific Antibody Molecular Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Medimmune Bispecific Antibody Molecular Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Medimmune Recent Developments
11.4 Merrimsck
11.4.1 Merrimsck Company Information
11.4.2 Merrimsck Overview
11.4.3 Merrimsck Bispecific Antibody Molecular Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Merrimsck Bispecific Antibody Molecular Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Merrimsck Recent Developments
11.5 Merus NV
11.5.1 Merus NV Company Information
11.5.2 Merus NV Overview
11.5.3 Merus NV Bispecific Antibody Molecular Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Merus NV Bispecific Antibody Molecular Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Merus NV Recent Developments
11.6 Genentech
11.6.1 Genentech Company Information
11.6.2 Genentech Overview
11.6.3 Genentech Bispecific Antibody Molecular Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Genentech Bispecific Antibody Molecular Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Genentech Recent Developments
11.7 Zhongshan Kangfang Biology Medicine
11.7.1 Zhongshan Kangfang Biology Medicine Company Information
11.7.2 Zhongshan Kangfang Biology Medicine Overview
11.7.3 Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Zhongshan Kangfang Biology Medicine Recent Developments
11.8 Sichuan Baili Pharmaceutical
11.8.1 Sichuan Baili Pharmaceutical Company Information
11.8.2 Sichuan Baili Pharmaceutical Overview
11.8.3 Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Sichuan Baili Pharmaceutical Recent Developments
11.9 Alphamab Oncology
11.9.1 Alphamab Oncology Company Information
11.9.2 Alphamab Oncology Overview
11.9.3 Alphamab Oncology Bispecific Antibody Molecular Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Alphamab Oncology Bispecific Antibody Molecular Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Alphamab Oncology Recent Developments
11.10 Amgen
11.10.1 Amgen Company Information
11.10.2 Amgen Overview
11.10.3 Amgen Bispecific Antibody Molecular Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Amgen Bispecific Antibody Molecular Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Amgen Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Bispecific Antibody Molecular Drug Industry Chain Analysis
12.2 Bispecific Antibody Molecular Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Bispecific Antibody Molecular Drug Production Mode & Process
12.4 Bispecific Antibody Molecular Drug Sales and Marketing
12.4.1 Bispecific Antibody Molecular Drug Sales Channels
12.4.2 Bispecific Antibody Molecular Drug Distributors
12.5 Bispecific Antibody Molecular Drug Customers
13 Market Dynamics
13.1 Bispecific Antibody Molecular Drug Industry Trends
13.2 Bispecific Antibody Molecular Drug Market Drivers
13.3 Bispecific Antibody Molecular Drug Market Challenges
13.4 Bispecific Antibody Molecular Drug Market Restraints
14 Key Findings in The Global Bispecific Antibody Molecular Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Bispecific Antibody Molecular Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of EGFR×HER3 Target
Table 3. Major Manufacturers of PD-1×CTLA-4 Target
Table 4. Major Manufacturers of HER2×HER3 Target
Table 5. Global Bispecific Antibody Molecular Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Bispecific Antibody Molecular Drug Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Bispecific Antibody Molecular Drug Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Bispecific Antibody Molecular Drug Revenue by Region (2024-2029) & (US$ Million)
Table 9. Global Bispecific Antibody Molecular Drug Revenue Market Share by Region (2018-2024)
Table 10. Global Bispecific Antibody Molecular Drug Revenue Market Share by Region (2024-2029)
Table 11. Global Bispecific Antibody Molecular Drug Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 12. Global Bispecific Antibody Molecular Drug Sales by Region (2018-2024) & (K Units)
Table 13. Global Bispecific Antibody Molecular Drug Sales by Region (2024-2029) & (K Units)
Table 14. Global Bispecific Antibody Molecular Drug Sales Market Share by Region (2018-2024)
Table 15. Global Bispecific Antibody Molecular Drug Sales Market Share by Region (2024-2029)
Table 16. Global Bispecific Antibody Molecular Drug Sales by Manufacturers (2018-2024) & (K Units)
Table 17. Global Bispecific Antibody Molecular Drug Sales Share by Manufacturers (2018-2024)
Table 18. Global Bispecific Antibody Molecular Drug Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Bispecific Antibody Molecular Drug Revenue Share by Manufacturers (2018-2024)
Table 20. Global Key Players of Bispecific Antibody Molecular Drug, Industry Ranking, 2021 VS 2022 VS 2024
Table 21. Bispecific Antibody Molecular Drug Price by Manufacturers 2018-2024 (US$/Unit)
Table 22. Global Bispecific Antibody Molecular Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Bispecific Antibody Molecular Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bispecific Antibody Molecular Drug as of 2022)
Table 24. Global Key Manufacturers of Bispecific Antibody Molecular Drug, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Bispecific Antibody Molecular Drug, Product Offered and Application
Table 26. Global Key Manufacturers of Bispecific Antibody Molecular Drug, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Bispecific Antibody Molecular Drug Sales by Type (2018-2024) & (K Units)
Table 29. Global Bispecific Antibody Molecular Drug Sales by Type (2024-2029) & (K Units)
Table 30. Global Bispecific Antibody Molecular Drug Sales Share by Type (2018-2024)
Table 31. Global Bispecific Antibody Molecular Drug Sales Share by Type (2024-2029)
Table 32. Global Bispecific Antibody Molecular Drug Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Bispecific Antibody Molecular Drug Revenue by Type (2024-2029) & (US$ Million)
Table 34. Global Bispecific Antibody Molecular Drug Revenue Share by Type (2018-2024)
Table 35. Global Bispecific Antibody Molecular Drug Revenue Share by Type (2024-2029)
Table 36. Bispecific Antibody Molecular Drug Price by Type (2018-2024) & (US$/Unit)
Table 37. Global Bispecific Antibody Molecular Drug Price Forecast by Type (2024-2029) & (US$/Unit)
Table 38. Global Bispecific Antibody Molecular Drug Sales by Application (2018-2024) & (K Units)
Table 39. Global Bispecific Antibody Molecular Drug Sales by Application (2024-2029) & (K Units)
Table 40. Global Bispecific Antibody Molecular Drug Sales Share by Application (2018-2024)
Table 41. Global Bispecific Antibody Molecular Drug Sales Share by Application (2024-2029)
Table 42. Global Bispecific Antibody Molecular Drug Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Bispecific Antibody Molecular Drug Revenue by Application (2024-2029) & (US$ Million)
Table 44. Global Bispecific Antibody Molecular Drug Revenue Share by Application (2018-2024)
Table 45. Global Bispecific Antibody Molecular Drug Revenue Share by Application (2024-2029)
Table 46. Bispecific Antibody Molecular Drug Price by Application (2018-2024) & (US$/Unit)
Table 47. Global Bispecific Antibody Molecular Drug Price Forecast by Application (2024-2029) & (US$/Unit)
Table 48. US & Canada Bispecific Antibody Molecular Drug Sales by Type (2018-2024) & (K Units)
Table 49. US & Canada Bispecific Antibody Molecular Drug Sales by Type (2024-2029) & (K Units)
Table 50. US & Canada Bispecific Antibody Molecular Drug Revenue by Type (2018-2024) & (US$ Million)
Table 51. US & Canada Bispecific Antibody Molecular Drug Revenue by Type (2024-2029) & (US$ Million)
Table 52. US & Canada Bispecific Antibody Molecular Drug Sales by Application (2018-2024) & (K Units)
Table 53. US & Canada Bispecific Antibody Molecular Drug Sales by Application (2024-2029) & (K Units)
Table 54. US & Canada Bispecific Antibody Molecular Drug Revenue by Application (2018-2024) & (US$ Million)
Table 55. US & Canada Bispecific Antibody Molecular Drug Revenue by Application (2024-2029) & (US$ Million)
Table 56. US & Canada Bispecific Antibody Molecular Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 57. US & Canada Bispecific Antibody Molecular Drug Revenue by Country (2018-2024) & (US$ Million)
Table 58. US & Canada Bispecific Antibody Molecular Drug Revenue by Country (2024-2029) & (US$ Million)
Table 59. US & Canada Bispecific Antibody Molecular Drug Sales by Country (2018-2024) & (K Units)
Table 60. US & Canada Bispecific Antibody Molecular Drug Sales by Country (2024-2029) & (K Units)
Table 61. Europe Bispecific Antibody Molecular Drug Sales by Type (2018-2024) & (K Units)
Table 62. Europe Bispecific Antibody Molecular Drug Sales by Type (2024-2029) & (K Units)
Table 63. Europe Bispecific Antibody Molecular Drug Revenue by Type (2018-2024) & (US$ Million)
Table 64. Europe Bispecific Antibody Molecular Drug Revenue by Type (2024-2029) & (US$ Million)
Table 65. Europe Bispecific Antibody Molecular Drug Sales by Application (2018-2024) & (K Units)
Table 66. Europe Bispecific Antibody Molecular Drug Sales by Application (2024-2029) & (K Units)
Table 67. Europe Bispecific Antibody Molecular Drug Revenue by Application (2018-2024) & (US$ Million)
Table 68. Europe Bispecific Antibody Molecular Drug Revenue by Application (2024-2029) & (US$ Million)
Table 69. Europe Bispecific Antibody Molecular Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 70. Europe Bispecific Antibody Molecular Drug Revenue by Country (2018-2024) & (US$ Million)
Table 71. Europe Bispecific Antibody Molecular Drug Revenue by Country (2024-2029) & (US$ Million)
Table 72. Europe Bispecific Antibody Molecular Drug Sales by Country (2018-2024) & (K Units)
Table 73. Europe Bispecific Antibody Molecular Drug Sales by Country (2024-2029) & (K Units)
Table 74. China Bispecific Antibody Molecular Drug Sales by Type (2018-2024) & (K Units)
Table 75. China Bispecific Antibody Molecular Drug Sales by Type (2024-2029) & (K Units)
Table 76. China Bispecific Antibody Molecular Drug Revenue by Type (2018-2024) & (US$ Million)
Table 77. China Bispecific Antibody Molecular Drug Revenue by Type (2024-2029) & (US$ Million)
Table 78. China Bispecific Antibody Molecular Drug Sales by Application (2018-2024) & (K Units)
Table 79. China Bispecific Antibody Molecular Drug Sales by Application (2024-2029) & (K Units)
Table 80. China Bispecific Antibody Molecular Drug Revenue by Application (2018-2024) & (US$ Million)
Table 81. China Bispecific Antibody Molecular Drug Revenue by Application (2024-2029) & (US$ Million)
Table 82. Asia Bispecific Antibody Molecular Drug Sales by Type (2018-2024) & (K Units)
Table 83. Asia Bispecific Antibody Molecular Drug Sales by Type (2024-2029) & (K Units)
Table 84. Asia Bispecific Antibody Molecular Drug Revenue by Type (2018-2024) & (US$ Million)
Table 85. Asia Bispecific Antibody Molecular Drug Revenue by Type (2024-2029) & (US$ Million)
Table 86. Asia Bispecific Antibody Molecular Drug Sales by Application (2018-2024) & (K Units)
Table 87. Asia Bispecific Antibody Molecular Drug Sales by Application (2024-2029) & (K Units)
Table 88. Asia Bispecific Antibody Molecular Drug Revenue by Application (2018-2024) & (US$ Million)
Table 89. Asia Bispecific Antibody Molecular Drug Revenue by Application (2024-2029) & (US$ Million)
Table 90. Asia Bispecific Antibody Molecular Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 91. Asia Bispecific Antibody Molecular Drug Revenue by Region (2018-2024) & (US$ Million)
Table 92. Asia Bispecific Antibody Molecular Drug Revenue by Region (2024-2029) & (US$ Million)
Table 93. Asia Bispecific Antibody Molecular Drug Sales by Region (2018-2024) & (K Units)
Table 94. Asia Bispecific Antibody Molecular Drug Sales by Region (2024-2029) & (K Units)
Table 95. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Sales by Type (2018-2024) & (K Units)
Table 96. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Sales by Type (2024-2029) & (K Units)
Table 97. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Revenue by Type (2018-2024) & (US$ Million)
Table 98. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Revenue by Type (2024-2029) & (US$ Million)
Table 99. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Sales by Application (2018-2024) & (K Units)
Table 100. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Sales by Application (2024-2029) & (K Units)
Table 101. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Revenue by Application (2018-2024) & (US$ Million)
Table 102. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Revenue by Application (2024-2029) & (US$ Million)
Table 103. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 104. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Revenue by Country (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Revenue by Country (2024-2029) & (US$ Million)
Table 106. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Sales by Country (2018-2024) & (K Units)
Table 107. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Sales by Country (2024-2029) & (K Units)
Table 108. MacroGenics Company Information
Table 109. MacroGenics Description and Major Businesses
Table 110. MacroGenics Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 111. MacroGenics Bispecific Antibody Molecular Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. MacroGenics Recent Developments
Table 113. Xencor Company Information
Table 114. Xencor Description and Major Businesses
Table 115. Xencor Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 116. Xencor Bispecific Antibody Molecular Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. Xencor Recent Developments
Table 118. Medimmune Company Information
Table 119. Medimmune Description and Major Businesses
Table 120. Medimmune Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 121. Medimmune Bispecific Antibody Molecular Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Medimmune Recent Developments
Table 123. Merrimsck Company Information
Table 124. Merrimsck Description and Major Businesses
Table 125. Merrimsck Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 126. Merrimsck Bispecific Antibody Molecular Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. Merrimsck Recent Developments
Table 128. Merus NV Company Information
Table 129. Merus NV Description and Major Businesses
Table 130. Merus NV Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 131. Merus NV Bispecific Antibody Molecular Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. Merus NV Recent Developments
Table 133. Genentech Company Information
Table 134. Genentech Description and Major Businesses
Table 135. Genentech Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 136. Genentech Bispecific Antibody Molecular Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. Genentech Recent Developments
Table 138. Zhongshan Kangfang Biology Medicine Company Information
Table 139. Zhongshan Kangfang Biology Medicine Description and Major Businesses
Table 140. Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 141. Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. Zhongshan Kangfang Biology Medicine Recent Developments
Table 143. Sichuan Baili Pharmaceutical Company Information
Table 144. Sichuan Baili Pharmaceutical Description and Major Businesses
Table 145. Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 146. Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 147. Sichuan Baili Pharmaceutical Recent Developments
Table 148. Alphamab Oncology Company Information
Table 149. Alphamab Oncology Description and Major Businesses
Table 150. Alphamab Oncology Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 151. Alphamab Oncology Bispecific Antibody Molecular Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 152. Alphamab Oncology Recent Developments
Table 153. Amgen Company Information
Table 154. Amgen Description and Major Businesses
Table 155. Amgen Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 156. Amgen Bispecific Antibody Molecular Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 157. Amgen Recent Developments
Table 158. Key Raw Materials Lists
Table 159. Raw Materials Key Suppliers Lists
Table 160. Bispecific Antibody Molecular Drug Distributors List
Table 161. Bispecific Antibody Molecular Drug Customers List
Table 162. Bispecific Antibody Molecular Drug Market Trends
Table 163. Bispecific Antibody Molecular Drug Market Drivers
Table 164. Bispecific Antibody Molecular Drug Market Challenges
Table 165. Bispecific Antibody Molecular Drug Market Restraints
Table 166. Research Programs/Design for This Report
Table 167. Key Data Information from Secondary Sources
Table 168. Key Data Information from Primary Sources
List of Figures
Figure 1. Bispecific Antibody Molecular Drug Product Picture
Figure 2. Global Bispecific Antibody Molecular Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Bispecific Antibody Molecular Drug Market Share by Type in 2022 & 2029
Figure 4. EGFR×HER3 Target Product Picture
Figure 5. PD-1×CTLA-4 Target Product Picture
Figure 6. HER2×HER3 Target Product Picture
Figure 7. Global Bispecific Antibody Molecular Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Bispecific Antibody Molecular Drug Market Share by Application in 2022 & 2029
Figure 9. Pancreatic Cancer
Figure 10. Breast Cancer
Figure 11. Colorectal Cancer
Figure 12. Non-Small Cell Lung Cancer
Figure 13. Solid Tumor
Figure 14. Others
Figure 15. Bispecific Antibody Molecular Drug Report Years Considered
Figure 16. Global Bispecific Antibody Molecular Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 17. Global Bispecific Antibody Molecular Drug Revenue 2018-2029 (US$ Million)
Figure 18. Global Bispecific Antibody Molecular Drug Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 19. Global Bispecific Antibody Molecular Drug Revenue Market Share by Region (2018-2029)
Figure 20. Global Bispecific Antibody Molecular Drug Sales 2018-2029 ((K Units)
Figure 21. Global Bispecific Antibody Molecular Drug Sales Market Share by Region (2018-2029)
Figure 22. US & Canada Bispecific Antibody Molecular Drug Sales YoY (2018-2029) & (K Units)
Figure 23. US & Canada Bispecific Antibody Molecular Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 24. Europe Bispecific Antibody Molecular Drug Sales YoY (2018-2029) & (K Units)
Figure 25. Europe Bispecific Antibody Molecular Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 26. China Bispecific Antibody Molecular Drug Sales YoY (2018-2029) & (K Units)
Figure 27. China Bispecific Antibody Molecular Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 28. Asia (excluding China) Bispecific Antibody Molecular Drug Sales YoY (2018-2029) & (K Units)
Figure 29. Asia (excluding China) Bispecific Antibody Molecular Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 30. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Sales YoY (2018-2029) & (K Units)
Figure 31. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 32. The Bispecific Antibody Molecular Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 33. The Top 5 and 10 Largest Manufacturers of Bispecific Antibody Molecular Drug in the World: Market Share by Bispecific Antibody Molecular Drug Revenue in 2022
Figure 34. Global Bispecific Antibody Molecular Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 35. Global Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2029)
Figure 36. Global Bispecific Antibody Molecular Drug Revenue Market Share by Type (2018-2029)
Figure 37. Global Bispecific Antibody Molecular Drug Sales Market Share by Application (2018-2029)
Figure 38. Global Bispecific Antibody Molecular Drug Revenue Market Share by Application (2018-2029)
Figure 39. US & Canada Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2029)
Figure 40. US & Canada Bispecific Antibody Molecular Drug Revenue Market Share by Type (2018-2029)
Figure 41. US & Canada Bispecific Antibody Molecular Drug Sales Market Share by Application (2018-2029)
Figure 42. US & Canada Bispecific Antibody Molecular Drug Revenue Market Share by Application (2018-2029)
Figure 43. US & Canada Bispecific Antibody Molecular Drug Revenue Share by Country (2018-2029)
Figure 44. US & Canada Bispecific Antibody Molecular Drug Sales Share by Country (2018-2029)
Figure 45. U.S. Bispecific Antibody Molecular Drug Revenue (2018-2029) & (US$ Million)
Figure 46. Canada Bispecific Antibody Molecular Drug Revenue (2018-2029) & (US$ Million)
Figure 47. Europe Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2029)
Figure 48. Europe Bispecific Antibody Molecular Drug Revenue Market Share by Type (2018-2029)
Figure 49. Europe Bispecific Antibody Molecular Drug Sales Market Share by Application (2018-2029)
Figure 50. Europe Bispecific Antibody Molecular Drug Revenue Market Share by Application (2018-2029)
Figure 51. Europe Bispecific Antibody Molecular Drug Revenue Share by Country (2018-2029)
Figure 52. Europe Bispecific Antibody Molecular Drug Sales Share by Country (2018-2029)
Figure 53. Germany Bispecific Antibody Molecular Drug Revenue (2018-2029) & (US$ Million)
Figure 54. France Bispecific Antibody Molecular Drug Revenue (2018-2029) & (US$ Million)
Figure 55. U.K. Bispecific Antibody Molecular Drug Revenue (2018-2029) & (US$ Million)
Figure 56. Italy Bispecific Antibody Molecular Drug Revenue (2018-2029) & (US$ Million)
Figure 57. Russia Bispecific Antibody Molecular Drug Revenue (2018-2029) & (US$ Million)
Figure 58. China Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2029)
Figure 59. China Bispecific Antibody Molecular Drug Revenue Market Share by Type (2018-2029)
Figure 60. China Bispecific Antibody Molecular Drug Sales Market Share by Application (2018-2029)
Figure 61. China Bispecific Antibody Molecular Drug Revenue Market Share by Application (2018-2029)
Figure 62. Asia Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2029)
Figure 63. Asia Bispecific Antibody Molecular Drug Revenue Market Share by Type (2018-2029)
Figure 64. Asia Bispecific Antibody Molecular Drug Sales Market Share by Application (2018-2029)
Figure 65. Asia Bispecific Antibody Molecular Drug Revenue Market Share by Application (2018-2029)
Figure 66. Asia Bispecific Antibody Molecular Drug Revenue Share by Region (2018-2029)
Figure 67. Asia Bispecific Antibody Molecular Drug Sales Share by Region (2018-2029)
Figure 68. Japan Bispecific Antibody Molecular Drug Revenue (2018-2029) & (US$ Million)
Figure 69. South Korea Bispecific Antibody Molecular Drug Revenue (2018-2029) & (US$ Million)
Figure 70. China Taiwan Bispecific Antibody Molecular Drug Revenue (2018-2029) & (US$ Million)
Figure 71. Southeast Asia Bispecific Antibody Molecular Drug Revenue (2018-2029) & (US$ Million)
Figure 72. India Bispecific Antibody Molecular Drug Revenue (2018-2029) & (US$ Million)
Figure 73. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2029)
Figure 74. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Revenue Market Share by Type (2018-2029)
Figure 75. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Sales Market Share by Application (2018-2029)
Figure 76. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Revenue Market Share by Application (2018-2029)
Figure 77. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Revenue Share by Country (2018-2029)
Figure 78. Middle East, Africa and Latin America Bispecific Antibody Molecular Drug Sales Share by Country (2018-2029)
Figure 79. Brazil Bispecific Antibody Molecular Drug Revenue (2018-2029) & (US$ Million)
Figure 80. Mexico Bispecific Antibody Molecular Drug Revenue (2018-2029) & (US$ Million)
Figure 81. Turkey Bispecific Antibody Molecular Drug Revenue (2018-2029) & (US$ Million)
Figure 82. Israel Bispecific Antibody Molecular Drug Revenue (2018-2029) & (US$ Million)
Figure 83. GCC Countries Bispecific Antibody Molecular Drug Revenue (2018-2029) & (US$ Million)
Figure 84. Bispecific Antibody Molecular Drug Value Chain
Figure 85. Bispecific Antibody Molecular Drug Production Process
Figure 86. Channels of Distribution
Figure 87. Distributors Profiles
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries